Quick Answer
Adaptimmune Therapeutics PLC reported Diluted EPS of $0.05 per share (loss) for fiscal year 2024.
Adaptimmune Therapeutics PLC Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2024 | -$0.05 | +44.4% |
| 2023 | -$0.09 | +47.1% |
| 2022 | -$0.17 | +0.0% |
| 2021 | -$0.17 | -13.3% |
| 2020 | -$0.15 | +31.8% |
| 2019 | -$0.22 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| June 30, 2025 | -$0.02 | -150.0% | +33.3% |
| March 31, 2025 | -$0.03 | +0.0% | -200.0% |
| September 30, 2024 | -$0.01 | +66.7% | -125.0% |
| June 30, 2024 | $0.04 | +300.0% | +233.3% |
| March 31, 2024 | -$0.03 | — | +0.0% |
| September 30, 2023 | -$0.03 | +25.0% | -50.0% |
| June 30, 2023 | -$0.02 | +60.0% | — |
| March 31, 2023 | $0.00 | +100.0% | +100.0% |
- Adaptimmune Therapeutics PLC showed an increase of +44.4% in Diluted EPS compared to the prior fiscal year.
- Over the 2019–2024 period, Adaptimmune Therapeutics PLC’s diluted eps has grown by 77.3% (from $0.22 per share (loss) to $0.05 per share (loss)).
- The most recent figure is from Adaptimmune Therapeutics PLC’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 24, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: